NewAmsterdam Pharma Company N.V. Payments to Acquire Marketable Securities
NewAmsterdam Pharma Company N.V. (NAMS) reported Payments to Acquire Marketable Securities of $113.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. payments to acquire marketable securities for the quarter ending 2026-06-30 was $51.18M, a 72.14% decline year-over-year.
- NewAmsterdam Pharma Company N.V. payments to acquire marketable securities for the quarter ending 2026-03-31 was $62.47M, a 548.78% increase year-over-year.
- NewAmsterdam Pharma Company N.V. payments to acquire marketable securities for the quarter ending 2025-12-31 was $71.54M.
- NewAmsterdam Pharma Company N.V. payments to acquire marketable securities for the quarter ending 2025-09-30 was $31.85M.
- NewAmsterdam Pharma Company N.V. payments to acquire marketable securities for fiscal 2025 was $296.73M, a 377.25% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. payments to acquire marketable securities for fiscal 2024 was $62.18M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $51.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $113.65M 10-Q · filed 2026-08-05 | $185.19M derived: sum of 3 quarters · filed 2026-08-05 | $217.05M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $62.47M 10-Q · filed 2026-05-07 | $134.01M derived: sum of 2 quarters · filed 2026-05-07 | $165.86M derived: sum of 3 quarters · filed 2026-05-07 | $349.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $71.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $103.39M derived: sum of 2 quarters · filed 2026-02-18 | $287.10M derived: sum of 3 quarters · filed 2026-08-05 | $296.73M 10-K · filed 2026-02-18 |
| 2025-09-30 | $31.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $215.56M derived: sum of 2 quarters · filed 2026-08-05 | $225.19M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $183.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $193.34M 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | $9.63M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $62.18M 10-K · filed 2026-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |